The antioxidant effects of resveratrol (3,5,4'-trihydroxy-trans-stilbene) contribute substantially to the health benefits of this compound. Resveratrol has been shown to be a scavenger of a number of free radicals. However, the direct scavenging activities of resveratrol are relatively poor. The antioxidant properties of resveratrol in vivo are more likely to be attributable to its effect as a gene regulator. Resveratrol inhibits NADPH oxidase-mediated production of ROS by down-regulating the expression and activity of the oxidase. This polyphenolic compound reduces mitochondrial superoxide generation by stimulating mitochondria biogenesis. Resveratrol prevents superoxide production from uncoupled endothelial nitric oxide synthase by up-regulating the tetrahydrobiopterin-synthesizing enzyme GTP cyclohydrolase I. In addition, resveratrol increases the expression of various antioxidant enzymes. Some of the gene-regulating effects of resveratrol are mediated by the histone/protein deacetylase sirtuin 1 or by the nuclear factor-E2-related factor-2. In this review article, we have also summarized the cardiovascular effects of resveratrol observed in clinical trials.
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Introduction
Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a polyphenol phytoalexin present in a variety of plant species and in red wine. Preclinical studies have demonstrated that resveratrol has protective effects in a number of disease models, including cardiovascular disease, diabetes, cancer and neurodegenerative diseases (Baur and Sinclair, 2006; Juhasz et al., 2010b) . Some beneficial effects have also been observed in clinical trials, although many discrepancies and conflicting information exist (Novelle et al., 2015) . The mechanisms of action of resveratrol are complex. Among these, antioxidant properties contribute substantially to the health benefits of resveratrol. In the present article we have reviewed the molecular mechanisms of resveratrol's antioxidant effects in the cardiovascular system.
Role of oxidative stress in cardiovascular disease
ROS, including free oxygen radicals, oxygen ions and peroxides, may have both physiological and pathological roles that are concentration-dependent. At moderate concentrations, ROS are important regulators of vascular homeostasis by acting as signalling molecules . In contrast, a high ROS concentration, due to excessive ROS production or malfunctioning antioxidant defence systems, causes oxidative stress. All cardiovascular risk factors lead to oxidative stress, which represents an important pathomechanism for cardiovascular disease. Therefore, pharmacological prevention of oxidative stress is of therapeutic interest .
ROS-producing systems
Among the ROS-producing enzyme systems in the vascular wall, NADPH oxidase, xanthine oxidase (XO), enzymes of the mitochondrial respiratory chain, and a dysfunctional endothelial NOS (eNOS) are of major importance .
NADPH oxidases
NADPH oxidases are multi-subunit enzyme complexes consisting of two membrane-bound subunits (NOX and p22phox) and several cytosolic regulatory subunits (Bedard and Krause, 2007; Drummond et al., 2011; Wingler et al., 2011) . In the vascular wall, vascular smooth muscle cells express NOX4 and NOX1, whereas endothelial cells express predominantly NOX4 and NOX2 . NADPH oxidases are major sources of ROS in the vasculature, producing superoxide (O 2 •¯) as well as hydrogen peroxide (by NOX4). Importantly, NADPH oxidase can trigger ROS production from other sources including uncoupled eNOS, XO (Landmesser et al., 2007) and mitochondria (Kroller-Schon et al., 2014; Schulz et al., 2014 ). An up-regulation of NADPH oxidase subunits has been observed in human atherosclerosis as well as in animal models of cardiovascular disease . In addition, XO can be released from the liver, and circulating XO can adhere to endothelial cells (White et al., 1996) . Atherosclerosis in human and experimental animals is associated with increased activity of both endothelial XO and plasma XO (Patetsios et al., 2001; Guzik et al., 2006) , suggesting a contribution of XO-derived ROS to cardiovascular disease. (Lubos et al., 2011) . The levels of mitochondrial ROS are of central importance to atherogenesis, heart function and other cardiovascular diseases. Loss of SOD2 causes perinatal lethality because of cardiac myopathy or congestive heart failure (Li et al., 1995; Nojiri et al., 2006) . Moreover, mitochondrial ROS also promote the activity of other ROS sources (e.g. NADPH oxidases, eNOS uncoupling and XO) (Kroller-Schon et al., 2014; Schulz et al., 2014) .
Mitochondria
Dysfunctional, uncoupled endothelial NOS
Under physiological conditions, eNOS produces NO, which represents a key element in the vasoprotective function of the endothelium (Li and Forstermann, 2000; Li et al., 2002) . Under pathological conditions, however, eNOS may become dysfunctional (Forstermann and Munzel, 2006; . Oxidative stress evidently contributes to endothelial dysfunction, primarily because of rapid oxidative inactivation of NO by an excess of O 2 •¯. In a second step, the persistant oxidative stress induces eNOS uncoupling (i.e. uncoupling of O 2 reduction from NO synthesis), thereby converting the eNOS enzyme to an O 2 •¯p roducer.
A number of mechanisms are implicated in eNOS uncoupling (Forstermann and Munzel, 2006; Li and Forstermann, 2009; Forstermann and Li, 2011) . Among these, tetrahydrobiopterin (BH 4 ) deficiency is likely to represent a major cause of eNOS uncoupling. BH 4 is biosynthesized from GTP with GTP cyclohydrolase I (GCH1) acting as the rate-limiting enzyme (Schmidt and Alp, 2007) . Under conditions associated with oxidative stress, peroxynitrite (and O 2
•¯l ess effectively) oxidizes BH 4 to BH 2 , leading to a deficiency of BH 4 (Laursen et al., 2001) . BH 2 can be reduced back to BH 4 by the enzyme dihydrofolate reductase. Thus, a deficit in BH 4 can be caused by enhanced BH 4 oxidation, by reduced BH 4 de novo synthesis (i.e. due to the down-regulation of GCH1) or by reduced BH 4 recycling from BH 2 (i.e. due to the down-regulation of dihydrofolate reductase) (Chalupsky and Cai, 2005) .
Uncoupling of eNOS is a crucial mechanism contributing to atherogenesis. It not only reduces NO production but also potentiates the pre-existing oxidative stress. The overproduction of ROS (e.g. O 2
•¯a nd subsequently peroxynitrite) by uncoupled eNOS in turn enhances the oxidation of BH 4 , creating a vicious BJP N Xia et al.
circle (Forstermann and Munzel, 2006; .
Antioxidant systems
The vascular wall contains a variety of enzymes, which can act as antioxidant defence systems and reduce the ROS burden.
SOD
SOD enzymes catalyse the dismutation of O 2 •¯i nto hydrogen peroxide, thereby providing a key antioxidant effect. There are three mammalian isoforms of SOD. The copper/zinc SOD (SOD1) is a soluble enzyme located in the cytoplasm and in the mitochondrial intermembrane space. SOD2 is found in the mitochondrial matrix. In contrast, the extracellular SOD (SOD3) is expressed in extracellular matrix, on the cell surface and in extracellular fluids .
Catalase
Catalase is an important cellular antioxidant enzyme and catalyses the decomposition of hydrogen peroxide to oxygen and water. The overexpression of catalase reduces atherosclerosis in apolipoprotein E-knockout (ApoE-KO) mice (Yang et al., 2004) .
Glutathione peroxidases
GSH peroxidase proteins convert hydrogen peroxide to water and lipid peroxides to their respective alcohols. GSH peroxidase 1 (GPx1) is the most abundant selenoperoxidase and is a key antioxidant enzyme in many cell types (Lubos et al., 2011 ).
NAD(P)H:quinone oxidoreductase 1 NAD(P)H:quinone oxidoreductase 1 (NQO1) is a flavoprotein that catalyses two-electron reduction of a broad range of substrates, including quinones. Quinonoid compounds generate aggressive ROS via redox cycling mechanisms and arylating nucleophiles. NQO1 reduces quinones to hydroquinones without the formation of semiquinones and ROS that are deleterious to cells. Therefore, the removal of quinones from a biological system by NQO1 is considered an important detoxification reaction (Ross and Siegel, 2004) .
Haem oxygenase 1
Haem oxygenase 1 (HO1) catalyses the degradation of the prooxidant haem into carbon monoxide, iron and biliverdin, which is subsequently converted to bilirubin. The antioxidant effects of HO1 also include the activation of transcriptional machinery that induces a range of antioxidant genes. The catabolism of haem provides protection to cells via numerous routes, including the induction of ferritin to store redox-active iron, the antioxidant actions of biliverdin and bilirubin and the anti-inflammatory and anti-apoptotic effects of carbon monoxide (Dunn et al., 2014) .
Nonenzymatic antioxidants
In addition to the antioxidant enzymes, nonenzymatic antioxidants are also important for the cell to control ROS levels. Nonenzyme low molecular weight antioxidant compounds include vitamins C and E, GSH, β-carotene and uric acid.
Resveratrol as a ROS scavenger
As a polyphenolic compound, resveratrol has been shown in in vitro systems to directly scavenge a variety of oxidants, including hydroxyl radical (
In a cell-free system using the Fenton reaction as a source of
• OH, resveratrol (at concentrations ≥300 μM) has been
shown to act as a scavenger and not an inhibitor of the Fenton reaction (Leonard et al., 2003 ). The hydroxyl radicalscavenging property of resveratrol is proposed to be due to its phenolic groups (Leonard et al., 2003) .
Resveratrol (at concentrations ≥100 μM) has been shown to scavenge O 2
•¯d irectly in a nonenzymatic, cell-free system (the potassium O 2 •¯s ystem) (Jia et al., 2008) . Interestingly, the O 2 •¯s cavenging activity of resveratrol is higher when the xanthine/XO system is used to generate O 2 •¯ ( Table 1 ) (Hung et al., 2002; Jia et al., 2008) . The difference in EC 50 values in these two systems can be explained by the fact that resveratrol not only has an O 2 •¯s cavenging activity but also suppresses O 2 •¯g eneration by inhibiting XO activity (at concentrations ≥50 μM) (Jia et al., 2008) . Table 1 Direct scavenging effects of resveratrol
Scavenging effect Reference
In cell-free assays, resveratrol effectively attenuates H 2 O 2 levels (Table 1) . Resveratrol (1 or 24 h incubation) also dosedependently decreases H 2 O 2 concentration in cultured arteries treated with paraquat or UV light (Ungvari et al., 2007) .
When incubated with authentic peroxynitrite in a cellfree system, resveratrol directly scavenges peroxynitrite, blocking the nitration of bovine serum albumin 20-fold more potently than N-acetyl-L-cysteine (Holthoff et al., 2010) . Resveratrol inhibits peroxynitrite-induced LDL oxidation (Brito et al., 2002) and inhibits peroxynitrite-induced cytotoxicity (Holthoff et al., 2010) .
In general, however, the direct antioxidant effects of resveratrol are rather poor (Table 1 ). The effects of resveratrol against oxidative injury in vivo are more likely to be attributable to its effects as a gene regulator rather than its direct ROS scavenging activity (Li et al., 2012; Xia et al., 2014b) .
Resveratrol as a gene regulator of the redox system
Many of resveratrol's protective effects in vivo are mediated by gene regulation. In whole-genome microarray experiments using liver samples from mice fed a high-calorie diet, the expression patterns of 782 out of 41 534 individual genes are changed significantly by resveratrol treatment. Remarkably, resveratrol prevents the effects of high caloric intake in 144 out of 153 significantly altered pathways . These results indicate that resveratrol is a powerful gene regulator (Xia et al., 2014b) .
Direct molecular targets of resveratrol
Resveratrol has been shown to induce various biological effects in preclinical studies. This is probably because resveratrol is a molecule with many targets (Bollmann et al., 2014) . Resveratrol is relatively hydrophobic because of its planar stilbene motif. Therefore, resveratrol has a relatively high affinity for hydrophobic pockets and binding sites in proteins. Moreover, the polar OH groups act as both hydrogen-bond donors and acceptors, which can form multiple interactions with amino acid side chains as well as backbone amide groups (Britton et al., 2015) . There have been around 20 proteins identified as having a specific affinity for resveratrol to date (Britton et al., 2015) .
For the antioxidant effects of resveratrol in the cardiovascular system, the NAD + -dependent histone/protein deacetylase sirtuin 1 (SIRT1) and the nuclear factor-E2-related factor-2 (Nrf2) are particularly important (see below). Another important resveratrol target for its cardiovascular effects is the oestrogen receptor (ER). A subpopulation of ERα is associated with caveolae in the endothelial plasma membrane and coupled to the eNOS in endothelial cells via a G protein (Wyckoff et al., 2001) . Resveratrol has been shown to rapidly activate eNOS by stimulating the membrane ER (Klinge et al., 2005; Klinge et al., 2008) . This represents one of the many mechanisms by which resveratrol enhances endothelial NO production (Xia et al., 2014a) . In addition to the direct vasoprotective effects of endothelial NO (Xia et al., 2014a) , ER-mediated NO production is likely to be involved in resveratrol-induced up-regulation of antioxidant proteins such as thioredoxin-1 and also HO1 Yu et al., 2010) .
SIRT1 as a resveratrol target
Among the known resveratrol targets, SIRT1 has received much attention. Resveratrol has been identified as a SIRT1 activator in an in vitro assay (Howitz et al., 2003) . However, later studies indicate that resveratrol directly activates SIRT1 only on certain substrates (Hubbard et al., 2013) . Indirectly, resveratrol may activate SIRT1 either through a signalling cascade involving PDE inhibition and subsequent elevation of cellular NAD + (Park et al., 2012) or by enhancing the binding of SIRT1 to lamin A, a protein activator of SIRT1 (Liu et al., 2012) . Resveratrol inhibits PDE1, PDE3 and PDE4 with IC 50 values of 6, 10 and 14 μM, respectively, without affecting the activity of PDE2 or PDE5 (Park et al., 2012) . Finally, the SIRT1-dependent effects of resveratrol in vivo may be also partially attributable to an up-regulation of SIRT1 expression (Csiszar et al., 2009; Xia et al., 2013) . Like resveratrol, SIRT1 is also a molecule with many targets, which is the molecular basis by which SIRT1 regulates a broad range of biological processes. SIRT1 modulates gene expression by targeting molecules such as histones, non-histone substrates (e.g. transcription factors and co-regulators) and SIRT1-interacting proteins (Zhang and Kraus, 2010) . For instance, SIRT1 deacetylates the RelA/p65 subunit of NF-κB, thereby suppressing inflammation (Yeung et al., 2004) . By targeting p53, sterol regulatory element-binding proteins, forkhead box O (FOXO) transcription factors and proliferatoractivated receptor-coactivator (PGC)-1α, SIRT1 modifies the expression of a number of enzymes involved in cell cycle/apoptosis, stress defence, anti-ageing processes, lipid metabolism and metabolic adaptation (Liang et al., 2009; Sinclair and Guarente, 2014) . In addition, SIRT1 target molecules also include some cytosolic proteins that are not transcription factors or cofactors including eNOS (Mattagajasingh et al., 2007) .
SIRT1-dependent up-regulation of antioxidant enzymes
Resveratrol regulates the expression and activity of a number of redox enzymes, thereby inhibiting ROS production and facilitating ROS detoxification (Figure 1) .
The up-regulation of SOD enzymes by resveratrol has been observed in cultured cells (Spanier et al., 2009; Ungvari et al., 2009; Xia et al., 2010) as well as in laboratory animals in vivo (Xia et al., 2010) . In cultured human endothelial cells, resveratrol (10-100 μM) increases the mRNA and protein levels of all three SOD enzymes (Spanier et al., 2009; Ungvari et al., 2009; Xia et al., 2010) . The up-regulation of SOD1 and SOD2, but not that of SOD3, by resveratrol is likely to be mediated by SIRT1 (Ungvari et al., 2009; Xia et al., 2010) . A recent study has shown that the SIRT1-induced up-regulation of SOD2 is partially mediated by FOXO1, a transcription factor regulated by SIRT1 (Hsu et al., 2010) .
Resveratrol enhances the expression of GPx1 and catalase in cultured human endothelial cells (Ungvari et al., 2007; Xia et al., 2010) as well as in cardiac tissue of ApoE-KO mice (Xia et al., 2010) . SIRT1 is likely to be involved in the up-regulation of GPx1 (Xia et al., 2010) and catalase (Alcendor et al., 2007) by resveratrol. The transcription factor FOXO3a, which is a BJP N Xia et al.
target molecule of SIRT1, has been implicated in the SIRT1-mediated up-regulation of catalase (Hasegawa et al., 2008; Liang et al., 2009 ).
Nrf2-dependent up-regulation of antioxidant enzymes
Nrf2 is an indirect target of resveratrol (Ungvari et al., 2010) . Under quiescent conditions, Nrf2 is localized in the cytoplasm through binding to Kelch-like erythroid cap'n'collar homologue (ECH) associated protein 1 (Keap 1). This interaction facilitates the ubiquitination and subsequent degradation of Nrf2. Treatment of cells with resveratrol leads to Nrf2 release from Keap 1 and Nrf2 translocation to the nucleus. The binding of Nrf2 to antioxidant response elements triggers antioxidant response element-dependent transcription of phase II and antioxidant defence enzymes. In cultured endothelial cells, resveratrol upregulates gene expression of antioxidant defence enzymes NQO1 and HO1 in an Nrf2-dependent manner (Ungvari et al., 2010) , although the molecular mechanism by which resveratrol activates Nrf2 is still unclear.
Lower concentrations of resveratrol (0.1-1 μM) are able to produce this effect (Ungvari et al., 2010) , whereas higher concentrations are needed to activate SIRT1 (high μM) (Howitz et al., 2003; Milne et al., 2007) . The in vivo relevance of resveratrol-induced Nrf2 activation has been demonstrated in mice fed a high-fat diet, in which the endothelial protective effects of resveratrol are largely diminished by genetic Nrf2 depletion (Ungvari et al., 2010) . Nrf2 may be also involved in GPx1 up-regulation (Gounder et al., 2012; Howden, 2013) , although direct evidence is still unavailable.
Effects of resveratrol on nonenzymatic antioxidants
Nrf2 activation by resveratrol also leads to an up-regulation of γ-glutamylcysteine synthetase, the rate-limiting enzyme for GSH synthesis (Ungvari et al., 2010) . Consistently, resveratrol increases endothelial GSH content (Ungvari et al., 2009 ).
Reduction of ROS production from vascular NADPH oxidases
The expression of NOX2 and NOX4 in the heart of hypercholesterolemic ApoE-KO mouse is reduced by resveratrol (100 mg·kg À1 ) (Xia et al., 2010) . This effect is likely to be independent of SIRT1; the down-regulation of NOX4 by resveratrol in endothelial cells (by 10-100 μM resveratrol) was not affected by SIRT1 inhibition or SIRT1 knockdown (Spanier et al., 2009; Xia et al., 2010) . Trauma haemorrhage in rats leads to an up-regulation of vascular NOX1, NOX2, NOX4, p22phox and p47phox. All these expressional changes can be normalized by resveratrol (30 mg·kg À1 i.v.) treatment (Yu et al., 2010) . The effect of resveratrol in trauma haemorrhagic rats is abolished by an ER antagonist or by a haem oxygenase enzyme inhibitor. Thus, it is possible that an ER-dependent up-regulation of HO1 is involved in the regulation of NADPH oxidase by resveratrol (Yu et al., 2010) .
In addition to its effect on NOX expression, resveratrol also modulates the activity of the NADPH oxidase enzyme complex. The activity of NOX4 relies on its association with p22phox, whereas the activity of NOX1 and NOX2 in Figure 1 Antioxidant effects of resveratrol. Resveratrol inhibits NADPH oxidase-mediated ROS production by down-regulation of the catalytic subunits (NOX proteins) and by inhibiting membrane translocation of Rac1 and inhibiting phosphorylation of p47phox. Resveratrol directly activates SIRT1 on certain substrates. It can also activate SIRT1 indirectly by potentiating the activation effect of lamin A or via a pathway involving PDE inhibition that leads to elevation of cellular NAD + . Among the established SIRT1 targets, FOXO transcription factors contribute to the antioxidative effects of resveratrol by up-regulating antioxidative enzymes (e.g. SOD2 and catalase, CAT) and eNOS. SIRT1 inhibits mitochondrial O 2
•¯p roduction by stimulating mitochondrial biogenesis, which is mediated by proliferator-activated receptor-coactivator-1α (PGC-1α) deacetylation and by NO-dependent mechanisms. The up-regulation of GCH1 leads to enhancement of BH 4 biosynthesis and prevention of eNOS uncoupling. In addition, resveratrol up-regulates a number of antioxidant enzymes by activating Nrf2.
vascular cells requires not only p22phox but also p47phox (or NOXO1), p67phox (or NOXA1) and Rac proteins (Brandes and Kreuzer, 2005) . Resveratrol (5 μM) reduces angiotensin II-and oxLDL-induced NADPH oxidase activation in cultured endothelial cells by inhibiting the membrane translocation of Rac (Chow et al., 2007) . In platelets, protein kinase C-mediated phosphorylation and activation of p47phox are prevented by resveratrol (0.15-0.25 μM) (Shen et al., 2007) .
Reduction of ROS production from mitochondria
Resveratrol stimulates mitochondrial biogenesis and thereby decreases mitochondrial ROS generation because mitochondrial proliferation reduces the flow of electrons per unit of mitochondria (Csiszar et al., 2009; Beauloye et al., 2011) . Mitochondrial biogenesis is impaired in the aorta of type 2 diabetic db/db mice, and this impairment can be normalized by resveratrol treatment (20 mg·kg À1 ) (Csiszar et al., 2009 ).
Resveratrol (10 μM) increases mitochondrial mass and mitochondrial DNA content and up-regulates the electron transport chain constituents and mitochondrial biogenesis factors in human cultured coronary arterial endothelial cells (Csiszar et al., 2009 ). SIRT1-dependent NO production (Csiszar et al., 2009; Xia et al., 2013) and SIRT1-mediated PGC-1α deacetylation (Beauloye et al., 2011) are implicated in resveratrol-stimulated mitochondrial biogenesis in endothelial cells.
Resveratrol decreases mitochondrial ROS levels not only by reducing ROS production but also by up-regulating antioxidant defence systems and thus accelerating ROS detoxification. The expression of SOD2 is enhanced by resveratrol in a SIRT1-dependent manner (Ungvari et al., 2009 ). An up-regulation of SOD2 per se increases mitochondrial generation of H 2 O 2 , which can easily penetrate mitochondrial membranes and diffuse into the cytoplasm. Interestingly, resveratrol treatment results in lower cytoplasmic H 2 O 2 levels (Ungvari et al., 2009) , which may result from increased H 2 O 2 detoxification by GPx1 in mitochondria and/or by enhanced H 2 O 2 inactivation by GPx1 and catalase in the cytoplasm. Both antioxidant enzymes are up-regulated by resveratrol (see above).
Reduction of ROS production from uncoupled eNOS
In the hypercholesterolaemic, atherosclerosis-prone ApoE-KO mice, uncoupled eNOS contributes significantly to the oxidative stress in cardiovascular tissues. ApoE-KO mice show increased ROS production in the aorta (Alp et al., 2004; Wohlfart et al., 2008) and the heart (Xia et al., 2010) . The NOS inhibitor L-NAME decreases O 2
•¯p roduction in both organs (Alp et al., 2004; Wohlfart et al., 2008; Xia et al., 2010) , indicating eNOS uncoupling in this pathological model. The major molecular mechanism of eNOS uncoupling in ApoE-KO mice has been found to be a deficiency of BH 4 , very likely due to increased oxidative degradation of the molecule (Alp et al., 2004) .
Treatment of ApoE-KO mice with resveratrol (30 or 100 mg·kg À1 ) enhances the expression of the BH 4 -synthesizing enzyme GCH1, increases the biosynthesis of BH 4 and reverses eNOS uncoupling (Xia et al., 2010) . Findings from cell culture studies demonstrate that the up-regulation of GCH1 by resveratrol is a SIRT1-dependent effect, because it can be reduced by the SIRT1 inhibitor sirtinol or by siRNAmediated SIRT1 knockdown (Xia et al., 2010) . At the same time, resveratrol also prevents BH 4 oxidation by reducing ROS levels, through both SIRT1-dependent (up-regulation of SOD1, SOD2, GPx1 and catalase) and SIRT1-independent (up-regulation of SOD3 and down-regulation of NOX4) mechanisms (Xia et al., 2010) . Resveratrol-induced up-regulation of GCH1 and elevation of BH 4 levels have also been observed in superior thyroid arteries obtained from patients with hypertension and dyslipidaemia (Carrizzo et al., 2013) .
Resveratrol doses and pharmacokinetics
The optimal resveratrol dose is not known. Because of the low bioavailability of resveratrol (Baur and Sinclair, 2006; Cottart et al., 2014) , very high resveratrol doses (up to 3000 mg) have been used in some clinical trials (Table 2) . A recent study indicates that such high doses may be unnecessary. Interestingly, the low dose (5 mg in humans or 0.07 mg·kg À1 in mice) has been shown to have even superior cancer chemopreventive efficacy than the high dose (1000 mg in humans or 14 mg·kg À1 in mice) (Cai et al., 2015) . Under certain conditions, resveratrol may display a hormetic action, protecting cells at lower doses while being detrimental at higher doses (Juhasz et al., 2010a) . About 1 h after oral ingestion of a single resveratrol dose by healthy volunteers, the maximum peak plasma concentrations (C max ) of 0.6 and 137 μM (for intakes of 5 mg and 1 g respectively) are reached (Cai et al., 2015) . Circulating resveratrol is still detectable as late as 24 h after resveratrol administration (average resveratrol concentrations 0.08 and 14 μM in the 5 mg and 1 g dose groups respectively) (Cai et al., 2015) .
The following mechanisms may contribute to the phenomenon that low resveratrol doses are effective, despite the rapid and extensive metabolism of resveratrol into sulfate and glucuronide conjugates. (i) Some resveratrol metabolites are biologically active, although not as effective as the parent molecule (Miksits et al., 2009; Lu et al., 2013) . (ii) Resveratrol and its metabolites can accumulate in tissues, resulting in enhanced concentrations compared to those in serum (Bresciani et al., 2014; Cai et al., 2015) . (iii) Some metabolites can be converted back to resveratrol in tissues (Miksits et al., 2009) .
Cardiovascular effects of resveratrol in humans
Preclinical studies have demonstrated a variety of protective effects in animal models of cardiovascular disease, including hypertension (Mizutani et al., 2000; Dolinsky et al., 2009; Dolinsky et al., 2013) , hypercholesterolaemia Juhasz et al., 2011) , atherosclerosis (Wang et al., 2005; Do et al., 2008) , ischaemic heart disease (Andreadou et al., 2015; Novelle et al., 2015) , diabetes (Su et al., 2006; Um et al., 2010) and metabolic syndrome (Novelle et al., 2015;  Table 2 Cardiovascular effects of resveratrol in humans 
Antioxidant effects of resveratrol BJP Pechanova et al., 2015) . These cardiovascular effects of resveratrol in laboratory animals have been reviewed in our previous article (Li et al., 2012) and in a recent publication (Zordoky et al., 2015) . Therefore, here we have summarized only the cardiovascular effects of resveratrol observed in clinical trials. As shown in Table 2 , the results of these studies are not always consistent, sometimes even contradictory. Moreover, the antioxidant effect of resveratrol does not always lead to a beneficial effect on cardiovascular health. For instance, exercise training induces a number of beneficial cardiovascular effects in healthy aged men, probably mediated partly through ROS-dependent mechanisms. A concomitant oral resveratrol supplementation, however, blunts part of these positive effects of exercise training (Gliemann et al., 2013; Olesen et al., 2014) .
Overall, the major limitation of the clinical studies currently available is the small sample size (Table 2) . Large clinical trials are clearly warranted to establish the clinical significance of resveratrol in humans.
Conclusion
The antioxidant effects of resveratrol are implicated in the health benefits of the compound. The direct ROS-scavenging effects of resveratrol are relatively poor. Resveratrol's antioxidant effects in vivo are more likely to be attributable to its regulation of redox genes leading to reduced ROS production from NADPH oxidases, uncoupled eNOS and the mitochondria. At the same time, an up-regulation of antioxidant enzymes by resveratrol accelerates the detoxification of ROS. 
